Literature DB >> 27519215

Localization of vascular endothelial growth factor in nontumorous human pituitaries.

S Vidal1, K Kovacs1, S M Cohen1, L Stefaneanu1, R V Lloyd2, B W Scheithauer2.   

Abstract

Vascular endothelial growth factor (VEGF) is a key mediator of endothelial cell proliferation, angiogenesis, and vascular permeability. Our aim was to investigate whether VEGF is expressed in various cell types of the human pituitary. Eight nontumorous pituitaries were investigated by histology, immunocytochemistry, double immunostaining, and immunoelectron microscopy.Immunocytochemistry, including double immunostaining, showed VEGF immunoreactive cells to be distributed throughout the adenohypophysis. Immunopositivity was evident in all adenohypophysial cell types, but was colocalized mainly with somatotroph and stellate cell antigen (i.e., growth hormone and S-100 protein). Weak to moderate VEGF immunoreactivity was also noted in posterior lobe pituicytes as well as in most endothelial and perivascular smooth muscle cells.In situ hybridization confirmed these findings in demonstrating a strong signal in corticotrophs, somatotrophs, and stellate cells. Immunoelectron microscopy showed VEGF to be present mainly within secretory granules where it colocalized with the full spectrum of adenohypophysial hormones. The subcellular distribution of VEGF suggests that hypothalamic factors play a role in its release from adenohypophysial cells. Further studies are required to examine the possible role of VEGF in affecting both the pituitary's vasculature and endocrine activity.

Entities:  

Keywords:  Pituitary; immunohistochemistry; in situ hybridization; vascular endothelial growth factor

Year:  1999        PMID: 27519215     DOI: 10.1007/BF02739823

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  39 in total

1.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Authors:  D Mukhopadhyay; B Knebelmann; H T Cohen; S Ananth; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.

Authors:  K Kovacs; L Stefaneanu; E Horvath; R V Lloyd; I Lancranjan; M Buchfelder; R Fahlbusch
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

3.  Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells.

Authors:  N Ferrara; D W Leung; G Cachianes; J Winer; W J Henzel
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

4.  Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization.

Authors:  K Kovacs; R Lloyd; E Horvath; S L Asa; L Stefaneanu; D W Killinger; H S Smyth
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

5.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

6.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

Authors:  N Ferrara; W J Henzel
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

7.  Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors.

Authors:  K A Elias; R I Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

8.  Pituitary thyrotroph hyperplasia mimicking prolactin-secreting adenoma.

Authors:  A Khalil; K Kovacs; A A Sima; G N Burrow; E Horvath
Journal:  J Endocrinol Invest       Date:  1984-08       Impact factor: 4.256

Review 9.  Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations.

Authors:  T Sano; S L Asa; K Kovacs
Journal:  Endocr Rev       Date:  1988-08       Impact factor: 19.871

10.  Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas.

Authors:  S Ezzat; H S Smyth; L Ramyar; S L Asa
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958

View more
  6 in total

1.  Vascularization of rat pituitary autografts.

Authors:  Matilde Lombardero; Andres Quintanar-Stephano; Sergio Vidal; Eva Horvath; Kalman Kovacs; Ricardo V Lloyd; Bernd W Scheithauer
Journal:  J Anat       Date:  2006-05       Impact factor: 2.610

2.  VEGF and CD31 association in pituitary adenomas.

Authors:  Carolina Cristina; María Inés Perez-Millan; Guillermina Luque; Raúl Ariel Dulce; Gustavo Sevlever; Silvia Inés Berner; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

3.  Angiopoietins are expressed in the normal rat pituitary gland.

Authors:  Sukriti Nag; Nima Nourhaghighi; Roopa Venugopalan; Sylvia L Asa; Duncan J Stewart
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

4.  Regulation of VEGF-A, VEGFR-I, thrombospondin-1, -2, and -3 expression in a human pituitary cell line (HP75) by TGFbeta1, bFGF, and EGF.

Authors:  Hidehisa Horiguchi; Long Jin; Katharina H Ruebel; Bernd W Scheithauer; Ricardo V Lloyd
Journal:  Endocrine       Date:  2004-07       Impact factor: 3.633

5.  Vascular Endothelial Growth Factor (VEGF) Expression in Human Pituitary Adenomas and Carcinomas.

Authors:  Ricardo V. Lloyd; Bernd W. Scheithauer; Takao Kuroki; Sergio Vidal; Kalman Kovacs; Lucia Stefaneanu
Journal:  Endocr Pathol       Date:  1999       Impact factor: 3.943

6.  Expression of Growth Factors in Normal and Neoplastic Pituitary Tissues.

Authors:  Wolfgang Saeger
Journal:  Endocr Pathol       Date:  2000       Impact factor: 4.056

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.